Charles E. Foulds
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Charles E. Foulds has a total of 257 co-authors. Here are the top co-authors by number of shared publications:
- Matthew James Ellis
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
67 shared publications - Xuxu Gou
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California
65 shared publications - Jonathan T. Lei
Baylor College of Medicine 1 Lester and Sue Smith Breast Center Houston, Texas
62 shared publications - Craig T. Vollert
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
61 shared publications - Meenakshi Anurag
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
61 shared publications - Beom-Jun Kim
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas
60 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S16 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
Effect of knocking down mutant p53 and re-expressing wild-type (WT) p53 in T47D Palbo-R cells on synergy and viability to the RP-6306 and gemcitabine combination
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S16 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
Effect of knocking down mutant p53 and re-expressing wild-type (WT) p53 in T47D Palbo-R cells on synergy and viability to the RP-6306 and gemcitabine combination
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
Statistical analyses of data in Figures 6B, 6C, and S3.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
Statistical analyses of data in Figures 6B, 6C, and S3.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
WEE1 mRNA and protein levels in ER+ breast cancer PDXs
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
WEE1 mRNA and protein levels in ER+ breast cancer PDXs
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S14 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
Synergy and viability analysis of RP-6306 and gemcitabine combination in MCF7 parental, EDR, and EDR Palbo-R cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
Synergy and viability analysis of RP-6306 and gemcitabine combination in MCF7 parental, EDR, and EDR Palbo-R cells
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
Potential mechanisms of palbociclib resistance in T47D and MCF7 EDR Palbo-R cell lines
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
Potential mechanisms of palbociclib resistance in T47D and MCF7 EDR Palbo-R cell lines
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S12 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
Synergy and viability analysis of AZD1775 and gemcitabine combination in T47D parental and Palbo-R cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
Synergy and viability analysis of AZD1775 and gemcitabine combination in T47D parental and Palbo-R cells
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
RP-6306 treatment did not restore the sensitivity of T47D Palbo-R cells to palbociclib
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
RP-6306 treatment did not restore the sensitivity of T47D Palbo-R cells to palbociclib
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
A model of PKMYT1 gene transcription regulated by ERα and E2F transcription factors
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
A model of PKMYT1 gene transcription regulated by ERα and E2F transcription factors
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S18 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
The combination of RP-6306 and gemcitabine increases apoptosis and activates DNA damage signaling in palbociclib-resistant T47D cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S18 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
The combination of RP-6306 and gemcitabine increases apoptosis and activates DNA damage signaling in palbociclib-resistant T47D cells
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
MCF7 EDR Palbo-R cell line displays cross-resistance to two other CDK4/6 inhibitors, in addition to being palbociclib-resistant
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
MCF7 EDR Palbo-R cell line displays cross-resistance to two other CDK4/6 inhibitors, in addition to being palbociclib-resistant